HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Germline and/or somatic mutations in BRCA1/BRCA2 in other cancer types also confer selective sensitivity to PARP inhibitors. T...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Med
Päätekijät: Davies, Helen, Glodzik, Dominik, Morganella, Sandro, Yates, Lucy R., Staaf, Johan, Zou, Xueqing, Ramakrishna, Manasa, Martin, Sancha, Boyault, Sandrine, Sieuwerts, Anieta M., Simpson, Peter T., King, Tari A., Raine, Keiran, Eyfjord, Jorunn E., Kong, Gu, Borg, Åke, Birney, Ewan, Stunnenberg, Hendrik G., van de Vijver, Marc J., Børresen-Dale, Anne-Lise, Martens, John W.M., Span, Paul N., Lakhani, Sunil R, Vincent-Salomon, Anne, Sotiriou, Christos, Tutt, Andrew, Thompson, Alastair M., Van Laere, Steven, Richardson, Andrea L., Viari, Alain, Campbell, Peter J, Stratton, Michael R., Nik-Zainal, Serena
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833945/
https://ncbi.nlm.nih.gov/pubmed/28288110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4292
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia